Kymriah®, a revolutionary drug to induce treatment remission in recalcitrant cancers – Lexology
|
Kymriah®, a revolutionary drug to induce treatment remission in recalcitrant cancers
Lexology In an unprecedented historic action, the US Food and Drug Administration (FDA) and Oncologic Drugs Advisory Committee (ODAC) unanimously approved CTL019 (tisagenlecleucel) or Kymriah®, an investigational chimeric antigen receptor T cell (CAR-T) … |
